This week, the ratings of 17 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Medicines Company (MDCO) is having a tough week. The company’s rating falls from a C to a D. Medicines Company develops products that improve specialized care. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDCO stock.

This is a rough week for Pfizer Inc. (PFE). The company’s rating falls to D from the previous week’s C. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. For more information, get Portfolio Grader’s complete analysis of PFE stock.

Impax Laboratories, Inc. (IPXL) slips from a D to a F this week. Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The company also gets F’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

Slipping from a C to a D rating, RedHill Biopharma Ltd. Sponsored ADR (RDHL) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RDHL stock.

This week, Agile Therapeutics, Inc.’s (AGRX) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

Cempra, Inc.’s (CEMP) rating weakens this week, dropping to a F versus last week’s C. Cempra, Inc. manufactures and markets pharmaceutical products. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CEMP stock.

TherapeuticsMD, Inc. (TXMD) declines this week from a C to a D. TherapeuticsMD, Inc. operates as a women’s healthcare product company in the United States. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of TXMD stock.

Oramed Pharmaceuticals Inc. (ORMP) gets weaker ratings this week as last week’s C drops to a D. Oramed Pharmaceuticals Inc. is a pharmaceutical company focused on the development of oral delivery solution. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ORMP stock.

Aralez Pharmaceuticals Inc. (ARLZ) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

This week, Aradigm Corporation (ARDM) drops from a D to a F rating. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDM stock.

KemPharm, Inc. (KMPH) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in earnings revisions, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

Slipping from a D to a F rating, Lipocine, Inc. (LPCN) takes a hit this week. Lipocine, Inc. is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

AcelRx Pharmaceuticals, Inc. (ACRX) declines this week from a D to a F. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

BioDelivery Sciences International, Inc. (BDSI) earns a F this week, moving down from last week’s grade of D. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.

EyeGate Pharmaceuticals, Inc. (EYEG) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EYEG stock.

This week, Dipexium Pharmaceuticals, Inc.’s (DPRX) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

VIVUS, Inc. (VVUS) experiences a ratings drop this week, going from last week’s C to a D. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.